A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Leukemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 420 (planned)
- Started
- May 19, 2021
- Main results expected
- Dec 29, 2028
- Fully finished
- Sep 22, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Measured over: Up to 4 years and 9 months
Phase 1: Number of Participants with AEs by Severity
Measured over: Up to 4 years and 9 months
Phase 1: Part 1: Percentage of Participants with Dose-Limiting Toxicity (DLT)
Measured over: Up to 28 days Cycle 1
Phase 2: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)
Measured over: Up to 4 years and 9 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04811560 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC